Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Test Different Doses of BI 1358894 and Find Out Whether They Reduce Symptoms in People With Borderline Personality Disorder

Phase 2

Completed

Conditions: Borderline Personality Disorder

Interventions: Drug: Placebo
Drug: BI 1358894

First Posted Date: 2020-09-28

Last Posted Date: 2024-01-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 390

Registration Number: NCT04566601

Locations: 🇺🇸
McLean Hospital, Belmont, Massachusetts, United States
🇦🇷
Fundación para el Estudio y Tratamiento de las Enfermedades Mentales (FETEM), Caba, Argentina
🇦🇷
Instituto Médico DAMIC S.R.L., Cordoba, Argentina

and more 64 locations

Post-marketing Surveillance of Ofev Capsules in Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype in Japan

Active, not recruiting

Conditions: Lung Diseases, Interstitial

Interventions: Drug: Nintedanib

First Posted Date: 2020-09-23

Last Posted Date: 2024-11-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 425

Registration Number: NCT04559581

Locations: 🇯🇵
Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan

A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung

Completed

Conditions: Squamous Non-small Cell Lung Cancer

Interventions: Drug: Second line (2L) afatinib
Drug: Second line chemotherapy

First Posted Date: 2020-09-17

Last Posted Date: 2022-01-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 200

Registration Number: NCT04552535

Locations: 🇺🇸
Cardinal Health Specialty Solutions, Dublin, Ohio, United States

A Study in Healthy Japanese Men to Test How Different Doses of BI 894416 Are Tolerated

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BI 894416

First Posted Date: 2020-09-07

Last Posted Date: 2023-08-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 8

Registration Number: NCT04540874

Locations: 🇯🇵
Clinical Research Hospital Tokyo, Tokyo, Shinjuku-ku, Japan

A Study in Healthy Men and Women Who Are Either Between 18 - 45 Years or Between 65 - 80 Years to Test How Different Doses of BI 474121 Are Tolerated

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BI 474121
Drug: Midazolam

First Posted Date: 2020-09-03

Last Posted Date: 2024-03-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 70

Registration Number: NCT04537897

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

ReAHEAD: A Study to Find Out Whether Education Improves Adherence to Dabigatran in People With Atrial Fibrillation Who Are Younger Than 75 Years

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Dabigatran

First Posted Date: 2020-08-31

Last Posted Date: 2023-05-26

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 898

Registration Number: NCT04532528

Locations: 🇨🇳
Buddhist Tzu Chi General Hospital, Hualien, Taiwan
🇨🇳
National Taiwan University Hospital-Hsin-Chu Branch, Hsinchu, Taiwan
🇨🇳
Pingtung Christian Hospital, Pingtung, Taiwan

and more 20 locations

A Study to Test How Well Empagliflozin Works in Japanese People With Type 2 Diabetes Who Are Older Than 65 Years

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Empagliflozin
Drug: Placebo

First Posted Date: 2020-08-28

Last Posted Date: 2024-05-02

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 129

Registration Number: NCT04531462

Locations: 🇯🇵
North Alps Medical Center Azumi Hospital, Nagano, Kitaazumi-gun, Japan
🇯🇵
Shinagawa East one Medical Clinic, Tokyo, Minato-ku, Japan
🇯🇵
Chubu Rosai Hospital, Aichi, Nagoya, Japan

and more 15 locations

Safety and Effectiveness of Nintedanib in Korean Patients

Completed

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: Nintedanib

First Posted Date: 2020-08-25

Last Posted Date: 2024-03-12

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 70

Registration Number: NCT04525547

Locations: 🇰🇷
Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of
🇰🇷
Inje University Ilsan Paik Hospital, Gyeonggi-do, Korea, Republic of
🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

and more 19 locations

A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression

Phase 2

Completed

Conditions: Depressive Disorder, Major

Interventions: Drug: BI 1358894
Drug: Placebo
Drug: Quetiapine

First Posted Date: 2020-08-20

Last Posted Date: 2024-03-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 389

Registration Number: NCT04521478

Locations: 🇺🇸
Atlanta Center, Atlanta, Georgia, United States
🇺🇸
Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States
🇨🇦
Braxia Scientific Corp. (CRTCE Mississauga), Mississauga, Ontario, Canada

and more 117 locations

EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

Phase 3

Completed

Conditions: Myocardial Infarction

Interventions: Drug: Placebo
Drug: Empagliflozin

First Posted Date: 2020-08-12

Last Posted Date: 2023-11-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 6522

Registration Number: NCT04509674

Locations: 🇺🇸
Charlotte Heart Group Research Center, Port Charlotte, Florida, United States
🇦🇺
Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
🇺🇸
Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, United States

and more 427 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy